Literature DB >> 8666318

Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain.

K E Sherman1, C Andreatta, J O'Brien, A Gutierrez, R Harris.   

Abstract

Patients coinfected with the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV) were studied with regard to nucleotide sequence variability in the E2/NS1 first hypervariable region of the HCV genome. The nucleotide variability within individual patients was compared to patients infected only with HCV. The proportion of predicted synonymous and nonsynonymous amino acid changes, and the relationship to putative high-antigenicity sites, were evaluated in the hypervariable envelope domain. Ninety-one clones from 10 patients with HCV/HIV coinfection were sequenced, following polymerase chain reaction (PCR) amplification of the hypervariable region. The control HCV group included 53 clones from 7 patients. Sequence analysis encompassed the region coding for amino acids 384 to 414. Consensus sequences from each patient were used as the internal standard for nonsynonymous amino acid codon variability. Cumulative proportional comparison at each amino acid site revealed increased variability in HCV RNA from patients with HCV/HIV coinfection versus HCV alone (P < .05). The greatest variability was observed at amino acids 386, 397, 400, 402, 405, 407, and 414, with >l0 percent clonal variation at these sites. Jameson-Wolf plots were used to predict putative high-antigenicity domains. Nonsynonymous clonal variation resulted in alteration of putative antigenic sites within the hypervariable region. All clones had at least one high-probability site. Clones with unique predicted antigenic domains were observed more frequently in HIV/HCV coinfected patients, and, independent of viral titer, were consistent with increased sequence variability. These data suggest an accumulation of envelope variants in the HCV/HIV coinfected patients, which could be related to ineffective viral clearance, and may help explain prior reports of interferon (IFN) resistance in this patient group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666318     DOI: 10.1002/hep.510230405

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

1.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  The hepatitis C virus 5'UTR genomic region remains highly conserved under HAART: a 4- to 8-year longitudinal study from HCV/HIV co-infected patients.

Authors:  Franco Moretti; Federico Bolcic; Lilia Mammana; Maria Belen Bouzas; Natalia Laufer; Jorge Quarleri
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

Review 3.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

4.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 5.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

6.  Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies.

Authors:  Q Mao; S C Ray; O Laeyendecker; J R Ticehurst; S A Strathdee; D Vlahov; D L Thomas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.

Authors:  Jason T Blackard; Gang Ma; Satarupa Sengupta; Christina M Martin; Eleanor A Powell; M Tarek Shata; Kenneth E Sherman
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

8.  Hepatitis C virus transmission bottlenecks analyzed by deep sequencing.

Authors:  Gary P Wang; Scott A Sherrill-Mix; Kyong-Mi Chang; Chris Quince; Frederic D Bushman
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

9.  Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.

Authors:  Cassandra B Jabara; Fengyu Hu; Katie R Mollan; Sara E Williford; Prema Menezes; Yan Yang; Joseph J Eron; Michael W Fried; Michael G Hudgens; Corbin D Jones; Ronald Swanstrom; Stanley M Lemon
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

10.  Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression.

Authors:  Dale M Netski; Qing Mao; Stuart C Ray; Robert S Klein
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.